Related references
Note: Only part of the references are listed.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Create, activate, destroy, repeat: Cdk1 controls proliferation by limiting transcription factor activity
Jennifer A. Benanti
CURRENT GENETICS (2016)
Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients
Maria Hernandez-Valladares et al.
BIOLOGICAL PROCEDURES ONLINE (2016)
Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows
Elise Aasebo et al.
JOURNAL OF PROTEOMICS (2016)
Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
B. M. Richine et al.
LEUKEMIA (2016)
Overexpression of protein kinase C epsilon improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction
H. He et al.
CELL DEATH & DISEASE (2016)
Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells
Chirag A. Shah et al.
ONCOTARGET (2016)
A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
Annette K. Brenner et al.
FRONTIERS IN IMMUNOLOGY (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis
Gina A. Smith et al.
BIOSCIENCE REPORTS (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Brenda W. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
Rashmi R. Shah et al.
DRUG SAFETY (2015)
Gene of the month: KIT
Riyaadh Roberts et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart
Min Cheng et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition
Leylah Drusbosky et al.
LEUKEMIA RESEARCH (2015)
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells
Sawa Ito et al.
STEM CELL RESEARCH (2015)
The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells
Hakon Reikvam et al.
STEM CELL RESEARCH (2015)
Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia
Katalin Boros et al.
ONCOTARGET (2015)
Targeting FLT3 to treat leukemia
Heiko Konig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias
R. Tibes et al.
INVESTIGATIONAL NEW DRUGS (2015)
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis
Rimma Berenstein
BIOMARKER INSIGHTS (2015)
The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta
Sooho Lee et al.
BMC CELL BIOLOGY (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
C-KIT Signaling in Cancer Treatment
Karmen Stankov et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Activation of the vascular niche supports leukemic progression and resistance to chemotherapy
Michael G. Poulos et al.
EXPERIMENTAL HEMATOLOGY (2014)
The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts
Joanna Zabkiewicz et al.
HAEMATOLOGICA (2014)
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
Giridharan Ramsingh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment
Miklos Kovacs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice
C. Sprissler et al.
BLOOD CANCER JOURNAL (2014)
Cyclin-dependent kinases
Marcos Malumbres
GENOME BIOLOGY (2014)
The biology and targeting of FLT3 in pediatric leukemia
Colleen E. Annesley et al.
FRONTIERS IN ONCOLOGY (2014)
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
Cedric Dos Santos et al.
BLOOD (2013)
β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis
Thomas Oellerich et al.
BLOOD (2013)
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers
Catherine Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia
Andreas Hedblom et al.
CELL CYCLE (2013)
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth
Noel A. Warfel et al.
CELL CYCLE (2013)
Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients
H. Reikvam et al.
CELL PROLIFERATION (2013)
Vascular endothelial growth factor signaling in acute myeloid leukemia
Kim R. Kampen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Casey B. Williams et al.
PHARMACOTHERAPY (2013)
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Yihai Cao
TRENDS IN MOLECULAR MEDICINE (2013)
Structural and Functional Properties of Platelet-Derived Growth Factor and Stem Cell Factor Receptors
Carl-Henrik Heldin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
Hakon Reikvam et al.
ONCOTARGET (2013)
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL
Yury I. Miller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
Adam del Corral et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα
Hanna S. Radomska et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis et al.
NATURE MEDICINE (2012)
PKC-Dependent Human Monocyte Adhesion Requires AMPK and Syk Activation
Mei-Ying Chang et al.
PLOS ONE (2012)
The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
K. J. Hatfield et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Therapeutic Potential for Protein Kinase C Inhibitor in Vascular Restenosis
Richard Qinxue Ding et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2011)
The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in
Armin Ehninger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells
Yongkun Wei et al.
NATURE CELL BIOLOGY (2011)
Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005)
Peter Hampson et al.
APOPTOSIS (2010)
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
Maike Buchner et al.
BLOOD (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB
Bjarte Skoe Erikstein et al.
LEUKEMIA RESEARCH (2010)
Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells
Yu-Chuen Huang et al.
TOXICOLOGY IN VITRO (2010)
The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity
Elisabeth Ersvaer et al.
TOXINS (2010)
Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation
Ernestina Saulle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn et al.
CANCER CELL (2009)
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3
Kristina Masson et al.
CELLULAR SIGNALLING (2009)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Soheil Meshinchi et al.
CLINICAL CANCER RESEARCH (2009)
T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance
Robert J. Salmond et al.
IMMUNOLOGICAL REVIEWS (2009)
Clinical implications of c-Kit mutations in acute myelogenous leukemia
Muriel Malaise et al.
Current Hematologic Malignancy Reports (2009)
The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low-Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Hanne Fredly et al.
CURRENT CANCER THERAPY REVIEWS (2009)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus
Yanfeng Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Lars Mollgard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Signal transduction in monocytes: the role of zinc ions
Hajo Haase et al.
BIOMETALS (2007)
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
Oystein Bruserud et al.
HAEMATOLOGICA (2007)
c-Kit - A hematopoietic cell essential receptor tyrosine kinase
Charlotte E. Edling et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk
L. Balaian et al.
LEUKEMIA (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
B van der Holt et al.
BLOOD (2005)
The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112
XP Yang et al.
CANCER RESEARCH (2005)
KDR and Sema3 genes expression in bone marrow stromal cells and hematopoietic cells from leukemia patients and normal individuals
Z Wang et al.
HEMATOLOGY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Normal and oncogenic forms of the receptor tyrosine kinase kit
J Lennartsson et al.
STEM CELLS (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A1
P Scapini et al.
JOURNAL OF IMMUNOLOGY (2004)
The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors
HM Hunter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status
N Glenjen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
T Padró et al.
LEUKEMIA (2002)
Inhibition of β2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr
CM Vines et al.
IMMUNITY (2001)
Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia:: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts (vol 67, pg 267, 2001)
B Foss et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
S Dias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
DJ Propper et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts
B Foss et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of AML cells - The present use in experimental studies and the possible importance for future therapeutic approaches
O Bruserud et al.
STEM CELLS (2001)
Share Paper
